Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Praxis Precision Medicines, Inc. (PRAX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-100"
06/16/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
06/09/2023 8-K Other Events  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-100"
04/17/2023 8-K Quarterly results
03/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Praxis Precision Medicines, Inc. 99 High Street, 30 th Floor Boston, MA 02110"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ESSENTIAL1 ESSENTIAL TREMOR TOPLINE RESULTS"
02/07/2023 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Ulixacaltamide Phase 2b Essential1study topline results for essential tremor expected in 1Q23&#59; Praxis to enter quiet period following market close on Thursday, February 9",
"PLATFORM PRAX-090 PRAX-222 PRAX-080 PRAX-020 PRAX-030 PRAX-050 PRAX-100"
11/28/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/07/2022 8-K Other Events  Interactive Data
08/12/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
07/26/2022 8-K Quarterly results
07/11/2022 8-K/A Quarterly results
06/06/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "PAGE 1 CONFIDENTIAL CORPORATE OVERVIEW JANUARY 2 0 2 2 PAGE 1"
01/07/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF PRAXIS PRECISION MEDICINES, INC."
12/17/2021 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study",
"PAGE 1 3 Q 2 0 2 1 CORPORATE UPDATE N"
08/30/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder"
06/10/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
Docs: "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results Expands pipeline with new indications for PRAX-114 and PRAX-944",
"PAGE 1CONFIDENTIAL C O R P O R A T E OVERVIEW M"
04/29/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy